Antipsychotic-induced weight gain in first-episode psychosis patients: A meta-analysis of differential effects of antipsychotic medications

Early Intervention in Psychiatry

Volumn 10, Issue 3, 2016, Pages 193-202

  Tek, Cenk ^a   Kucukgoncu, Suat ^a   Guloksuz, Sinan ^a   Woods, Scott W ^a   Srihari, Vinod H ^a   Annamalai, Aniyizhai ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Ethnicity; Haloperidol; Obesity; Schizophrenia; Side effect

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; BLONANSERIN; CHLORPROMAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

BODY MASS; DRUG EFFICACY; DRUG SAFETY; ETHNICITY; HUMAN; META ANALYSIS; OBESITY; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; DRUG EFFECTS; PSYCHOTIC DISORDERS;

ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; HUMANS; PSYCHOTIC DISORDERS; WEIGHT GAIN;

EID: 84929259258     PISSN: 17517885     EISSN: 17517893     Source Type: Journal    
DOI: 10.1111/eip.12251     Document Type: Review

References (62)

1. Chwastiak LA, Tek C. The unchanging mortality gap for people with schizophrenia. Lancet 2009; 374: 590-592.
2. Tiihonen J, Lonnqvist J, Wahlbeck K etal. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374: 620-627.
3. Lahti M, Tiihonen J, Wildgust H etal. Cardiovascular morbidity, mortality and pharmacotherapy in patients with schizophrenia. Psychol Med 2012; 42: 2275-2285.
4. Srihari VH, Phutane VH, Ozkan B etal. Cardiovascular mortality in schizophrenia: defining a critical period for prevention. Schizophr Res 2013; 146: 64-68.
5. Ratliff JC, Palmese LB, Reutenauer EL, Srihari VH, Tek C. Obese schizophrenia spectrum patients have significantly higher 10-year general cardiovascular risk and vascular ages than obese individuals without severe mental illness. Psychosomatics 2013; 54: 67-73.
6. Baganz CN, Norris JM. A study of malnutrition in chronic schizophrenia. Am J Psychiatry 1943; 99: 534-541.
7. Padmavati R, McCreadie RG, Tirupati S. Low prevalence of obesity and metabolic syndrome in never-treated chronic schizophrenia. Schizophr Res 2010; 121: 199-202.
8. Daumit GL, Dickerson FB, Wang NY etal. A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med 2013; 368: 1594-1602.
9. Jean-Baptiste M, Tek C, Liskov E etal. A pilot study of a weight management program with food provision in schizophrenia. Schizophr Res 2007; 96: 198-205.
10. Ratliff JC, Palmese LB, Tonizzo KM, Chwastiak L, Tek C. Contingency management for the treatment of antipsychotic-induced weight gain: a randomized controlled pilot study. Obes Facts 2012; 5: 919-927.
11. Knowler WC, Barrett-Connor E, Fowler SE etal. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
12. Alvarez-Jimenez M, Gonzalez-Blanch C, Vazquez-Barquero JL etal. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: a randomized controlled trial. J Clin Psychiatry 2006; 67: 1253-1260.
13. Lovell K, Wearden A, Bradshaw T etal. An exploratory randomized controlled study of a healthy living intervention in early intervention services for psychosis: the INTERvention to encourage ACTivity, improve diet, and reduce weight gain (INTERACT) study. J Clin Psychiatry 2014; 75: 498-505.
14. Allison DB, Mentore JL, Heo M etal. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-1696.
15. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment-pharmacological mechanisms. Pharmacol Ther 2010; 125: 169-179.
16. Deng C, Weston-Green K, Huang X-F. The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain? Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 1-4.
17. He M, Deng C, Huang XF. The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain. CNS Drugs 2013; 27: 423-434.
18. Ratliff JC, Barber JA, Palmese LB, Reutenauer EL, Tek C. Association of prescription H1 antihistamine use with obesity: results from the National Health and Nutrition Examination Survey. Obesity (Silver Spring) 2010; 18: 2398-2400.
19. Lieberman JA, Stroup TS, McEvoy JP etal. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223.
20. Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O etal. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naive population. Schizophr Res 2008; 99: 13-22.
21. Bak M, Fransen A, Janssen J, van Os J, Drukker M. Almost all antipsychotics result in weight gain: a meta-analysis. PLoS ONE 2014; 9: e94112, 1-19.
22. Tarricone I, Ferrari Gozzi B, Serretti A, Grieco D, Berardi D. Weight gain in antipsychotic-naive patients: a review and meta-analysis. Psychol Med 2010; 40: 187-200.
23. Woods SW, Breier A, Zipursky RB etal. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiatry 2003; 54: 453-464.
24. Strassnig M, Miewald J, Keshavan M, Ganguli R. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophr Res 2007; 93: 90-98.
25. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
26. Leucht S, Cipriani A, Spineli L etal. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382: 951-962.
27. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
28. Abrams KR, Gillies CL, Lambert PC. Meta-analysis of heterogeneously reported trials assessing change from baseline. Stat Med 2005; 24: 3823-3844.
29. McGlashan TH, Zipursky RB, Perkins D etal. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006; 163: 790-799.
30. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
31. Fleischhacker WW, Siu CO, Boden R, Pappadopulos E, Karayal ON, Kahn RS. Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. Int J Neuropsychopharmacol 2013; 16: 987-995.
32. Grootens KP, van Veelen NM, Peuskens J etal. Ziprasidone vs. olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial. Schizophr Bull 2011; 37: 352-361.
33. Patel JK, Buckley PF, Woolson S etal. Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophr Res 2009; 111: 9-16.
34. Schooler N, Rabinowitz J, Davidson M etal. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry 2005; 162: 947-953.
35. Zipursky RB, Gu H, Green AI etal. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 2005; 187: 537-543.
36. Lieberman JA, Phillips M, Gu H etal. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs. chlorpromazine. Neuropsychopharmacology 2003; 28: 995-1003.
37. Josiassen RC, Shaughnessy RA, Filymer DM etal. Early intervention with second-generation antipsychotics in first-episode psychosis: results of an 8-week naturalistic study. Early Interv Psychiatry 2010; 4: 57-63.
38. Huq ZU. A trial of low doses of risperidone in the treatment of patients with first-episode schizophrenia, schizophreniform disorder, or schizoaffective disorder. J Clin Psychopharmacol 2004; 24: 220-224.
39. Lee HY, Ham BJ, Kang RH etal. Trial of aripiprazole in the treatment of first-episode schizophrenia. Psychiatry Clin Neurosci 2010; 64: 38-43.
40. McGorry PD, Cocks J, Power P, Burnett P, Harrigan S, Lambert T. Very low-dose risperidone in first-episode psychosis: a safe and effective way to initiate treatment. Schizophr Res Treatment 2011; 2011: 631690.
41. Ou JJ, Xu Y, Chen HH etal. Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with first-episode schizophrenia. Psychopharmacology (Berl) 2013; 225: 627-635.
42. Sengupta SM, Klink R, Stip E, Baptista T, Malla A, Joober R. Weight gain and lipid metabolic abnormalities induced by olanzapine in first-episode, drug-naive patients with psychotic disorders. Schizophr Res 2005; 80: 131-133.
43. Takahashi H, Oshimo T, Ishigooka J. Efficacy and tolerability of aripiprazole in first-episode drug naive patients with schizophrenia: an open-label trial. Clin Neuropharmacol 2009; 32: 149-150.
44. Tauscher-Wisniewski S, Kapur S, Tauscher J etal. Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. J Clin Psychiatry 2002; 63: 992-997.
45. Yap HL, Mahendran R, Lim D etal. Risperidone in the treatment of first episode psychosis. Singapore Med J 2001; 42: 170-173.
46. Zalsman G, Carmon E, Martin A, Bensason D, Weizman A, Tyano S. Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. J Child Adolesc Psychopharmacol 2003; 13: 319-327.
47. Zhao T, Park TW, Yang JC etal. Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial. Int Clin Psychopharmacol 2012; 27: 184-190.
48. Sanz-Fuentenebro J, Taboada D, Palomo T etal. Randomized trial of clozapine vs. risperidone in treatment-naive first-episode schizophrenia: results after one year. Schizophr Res 2013; 149: 156-161.
49. Gasquet I, Haro JM, Novick D, Edgell ET, Kennedy L, Lepine JP. Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Int Clin Psychopharmacol 2005; 20: 199-205.
50. Vinay HR, Sundar GSK, Behere RV etal. Effect of risperidone on metabolic parameters in antipsychotic-naïve schizophrenia: a prospective one year follow-up study. Asian J Psychiatr 2011; 4: 73-74.
51. Ingole S, Belorkar NR, Waradkar P, Shrivastava M. Comparison of effects of olanzapine and risperidone on body mass index and blood sugar level in schizophrenic patients. Indian J Physiol Pharmacol 2009; 53: 47-54.
52. Hori H, Ueda N, Yoshimura R etal. Olanzapine orally disintegrating tablets (Zyprexa Zydis) rapidly improve excitement components in the acute phase of first-episode schizophrenic patients: an open-label prospective study. World J Biol Psychiatry 2009; 10: 741-745.
53. Perez-Iglesias R, Ortiz-Garcia de la Foz V, Martinez Garcia O etal. Comparison of metabolic effects of aripiprazole, quetiapine and ziprasidone after 12 weeks of treatment in first treated episode of psychosis. Schizophr Res 2014; 159: 90-94.
54. Ninomiya Y, Miyamoto S, Tenjin T etal. Long-term efficacy and safety of blonanserin in patients with first-episode schizophrenia: a 1-year open-label trial. Psychiatry Clin Neurosci 2014; 68: 841-849.
55. Liu J, Sun J, Shen X etal. Randomized controlled trial comparing changes in serum prolactin and weight among female patients with first-episode schizophrenia over 12 months of treatment with risperidone or quetiapine. Shanghai Arch Psychiatry 2014; 26: 88-94.
56. Rasmussen H, Ebdrup BH, Oranje B, Pinborg LH, Knudsen GM, Glenthoj B. Neocortical serotonin2A receptor binding predicts quetiapine associated weight gain in antipsychotic-naive first-episode schizophrenia patients. Int J Neuropsychopharmacol 2014; 17: 1729-1736.
57. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80mg/day and 160mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999; 20: 491-505.
58. Pfizer I. Goedon Prescribing Information, 2014 [Updated 2014 January, 2014; cited 8 August 2014.] Available from URL: http://labeling.pfizer.com/ShowLabeling.aspx?id=584
59. Zhang JY, Kowal DM, Nawoschik SP, Lou Z, Dunlop J. Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem Pharmacol 2006; 71: 521-529.
60. Stroup TS, McEvoy JP, Ring KD etal. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 2011; 168: 947-956.
61. Álvarez-Jiménez M, González-Blanch C, Crespo-Facorro B etal. Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs 2008; 22: 547-563.
62. Birchwood M, Todd P, Jackson C. Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry Suppl 1998; 172: 53-59.